Your browser is not supported. please upgrade to the latest version of Google Chrome, Mozilla Firefox, Apple Safari or Microsoft Edge.
Reata Pharmaceuticals
Pharmaceutical/Medical Devices
About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.



View Company Website
N/A

Average Breakdown

N/A
Diversity Across Organization
N/A
Diversity in Leadership
N/A
Work / Life Balance
N/A
Overall Inclusiveness
N/A
D&I Benefits & Resources

You've Been Timed Out

Please login to continue